Pharmacological treatment of childhood absence epilepsy

References

• Commission on Classification and Terminology of the InternationalLeague Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia30, 389–399 (1989).
   PubMed Web of Science ®Google Scholar
• Koutroumanidis M, Bourvari G, Tan SV. Idiopathic generalized epilepsies: clinical and electroencephalogram diagnosis and treatment. Expert Rev. Neurotherapeutics5(6), 753–767 (2005).
   PubMedGoogle Scholar
• Panayiotopoulos CP. Childhood absence epilepsy. In: The Epilepsies. Seizures, Syndromes and Management (First Edition). Bladon Medical Publishing, Oxford, UK, 301 (2005).
   Google Scholar
• Grosso S, Galimberti D, Vezzosi P et al. Childhood absence epilepsy: evolution and prognostic factors. Epilepsia46(11), 1796–1801 (2005).
   Google Scholar
• Olsson I. Epidemiology of absence epilepsy. Concept and incidence. Acta. Paediatr. Scand.77, 860–866 (1988).
   Google Scholar
• Loiseau J, Loiseau P, Guyot M et al. Survey of seizure disorders in the French south west. Incidence of epileptic syndromes. Epilepsia31, 391–396 (1990).
   Google Scholar
• Blom S, Heijbel J, Bergfors PG. Incidence of epilepsy in children: a follow-up study three years after the first seizure. Epilepsia19, 343–350 (1978).
   Google Scholar
• Callenbach PMC, Geerts AT, Arts WFM et al. Familial occurrence of epilepsy in children with newly diagnosed multiple seizures: Dutch study of epilepsy in childhood. Epilepsia39(3), 331–336 (1998).
   PubMed Web of Science ®Google Scholar
• Berg AT, Shinnar S, Levy SR et al. Newly diagnosed epilepsy in children: presentation at diagnosis. Epilepsia40, 445–452 (1999).
   PubMed Web of Science ®Google Scholar
• Jallon P, Latour P. Epidemiology of idiopathic generalized epilepsies. Epilepsia46(Suppl. 9), 10–14 (2005).
   PubMed Web of Science ®Google Scholar
• Gardiner M. Genetics of idiopathic generalized epilepsies. Epilepsia46(Suppl. 9), 15–20 (2005).
   PubMedGoogle Scholar
• Blumenfeld H. Cellular and network mechanisms of spike-wave seizures. Epilepsia46(Suppl. 9), 21–23 (2005).
   PubMedGoogle Scholar
• Meeren H, Luijtelaar G, Lopes da Silva F et al. Evolving concepts on the pathophysiology of absence seizures. Arch. Neurol.62, 371–376 (2005).
   PubMedGoogle Scholar
• Huguenard JR. Neuronal circuitry of thalamocortical epilepsy and mechanisms of anti-absence drug action. Adv. Neurol.79, 991–999 (1999).
   PubMedGoogle Scholar
• Meeren HKM, Pijn JPM, Van Luijtelaar ELJM et al. Cortical focus drives widespread corticothalamic networks during spontaneous absence seizures in rats. J. Neurosci.22(4), 1480–1495 (2002).
   PubMed Web of Science ®Google Scholar
• Manning JPA, Richards DA, Leresche N et al. Cortical-area specific block of genetically determined absence seizures by ethosuximide. Neuroscience123(1), 5–9 (2004).
   Google Scholar
• Panayiotopoulos CP. Childhood absence epilepsy. In: The Epilepsies. Seizures, Syndromes and Management (First Edition). Bladon Medical Publishing, Oxford, UK, 278 (2005).
   Google Scholar
• Manning JP, Richards DA, Bowery NG. Pharmacology of absence epilepsy. Trends Pharmacol. Sci.24, 542–549 (2003).
   PubMed Web of Science ®Google Scholar
• Vanasse CM, Beland R, Carmant L et al. Impact of childhood epilepsy on reading and phonological processing abilities. Epilepsy Behavior7(2), 288–296 (2005).
   PubMed Web of Science ®Google Scholar
• Mirsky AF, Duncan CC, Levav ML. Neuropsychological and psychophysiological aspects of absence epilepsy. In: Typical Absences and Related Syndromes. Duncan JS, Panayiotopoulos CP (Eds). Churchill Communications, London, UK, 112–119 (1995).
   Google Scholar
• Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia46(Suppl. 9), 161–168 (2005).
   PubMed Web of Science ®Google Scholar
• Wirrell E, Camfield C, Camfield P et al. Prognostic significance of failure of the initial antiepileptic drug in children with absence epilepsy. Epilepsia42(6), 760–763 (2001).
   PubMed Web of Science ®Google Scholar
• Treatment of typical absences differs from that of other types of seizures. Drugs and Therapy Perspectives18(4), 16–20 (2002).
   Google Scholar
• Erenberg G, Rothner A, Henry C et al. Valproic acid in the treatment of intractable absence seizures in children. Am. J. Dis. Child136, 526–529 (1982).
   Google Scholar
• Epilim. Product monograph. Sanofi Winthrop Ltd, Surrey, UK (1995).
   Google Scholar
• Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs47, 332–372 (1994).
   PubMed Web of Science ®Google Scholar
• Dulac O, Rey E, Chiron C. Antiepileptic drug interactions in children, In: Antiepileptic Drugs. Majkowski J (Ed.). Cambridge University Press, UK (2005).
   Google Scholar
• Alsdorf R, Wyszynski D, Teratogenicity of sodium valproate. Expert Opin. Drug Safety4(2), 345–353 (2005).
   PubMedGoogle Scholar
• Covanis A, Skiadas K, Loli N et al. Absence epilepsy: early prognostic signs. Seizure1, 281–289 (1992).
   PubMedGoogle Scholar
• Posner EB, Mohamed K, Marson AG. A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine. Seizure14(2), 117–122 (2005).
   Google Scholar
• Sato S, White BG, Penry JK et al. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology32, 157–163 (1982).
   PubMed Web of Science ®Google Scholar
• Callaghan N, O’Hare J, O’Driscoll D et al. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev. Med. Child Neurol.24, 830–836 (1982).
   PubMed Web of Science ®Google Scholar
• Martinovic Z. Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: Advances in Epileptology: 14th Epilepsy International Symposium. Parsonage M (Ed.). Raven Press, NY, USA, 301–305 (1983).
   Google Scholar
• Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: two neurochemical studies of the mechanism of action. Epilepsia27, 490–497 (1986).
   PubMed Web of Science ®Google Scholar
• Schlumberger E, Chavez F, Palacios L et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia35, 359–367 (1994).
   PubMed Web of Science ®Google Scholar
• Gericke CA, Pickard F, de Saint-Martin A et al. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled, open study. Epileptic Disorders1(3), 159–166 (1999).
   PubMed Web of Science ®Google Scholar
• Frank LM, Enlow T, Holmes GL et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia40, 973–979 (1999).
   PubMed Web of Science ®Google Scholar
• Coppola G, Auricchio G, Federico R et al. Lamotrigine versus Valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomised, parallel-group study, Epilepsia45(9), 1049–1053 (2004).
   PubMedGoogle Scholar
• Besag FMC, Dulac O, Alving J et al. Long term safety and efficacy of lamotrigine (lamictal) in paediatric patients with epilepsy. Seizure6, 51–56 (1997).
   PubMedGoogle Scholar
• Duchowny M, Gilman J, Messenheimer J et al. Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy. J. Child Neurol.17, 278–285 (2002).
   PubMedGoogle Scholar
• Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia36(Suppl. 2), S2–S12 (1995).
   PubMed Web of Science ®Google Scholar
• Richens A, Ethosuximide and valproate, In: Typical Absences and Related Epileptic Syndromes. Duncan JS, Panayiotopoulos CP (Eds). Churchill Communications Europe, London, UK, 361 (1995).
   Google Scholar
• Wallace SJ. Mioclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res.29, 147–154 (1998).
   PubMed Web of Science ®Google Scholar
• Coulter DA. Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J. Child Neurol.12(Suppl. 1), S2–S9 (1997).
   PubMedGoogle Scholar
• Mikkelsen B, Birket-Smith E, Bradt S et al. Clonazepam in the treatment of epilepsy. A controlled clinical trial in simple absences, bilateral massive epileptic myoclonus, and atonic seizures. Arch. Neurol.33(5), 322–325 (1976).
   PubMedGoogle Scholar
• Hitiris N, Brodie MJ. Evidence-based treatment of idiopathic generalized epilepsies with older antiepileptic drugs, Epilepsia46(Suppl. 9), 149–153 (2005).
   PubMed Web of Science ®Google Scholar
• Lombroso CT, Forxythe I. A long-term follow-up of acetazolamide (diamox) in the treatment of epilepsy. Epilepsia1, 493–500 (1960).
   PubMed Web of Science ®Google Scholar
• Perucca E. Acetozolamide, Sulthiame. In: Comprehensive Epileptology. Dam M, Gram L (Eds). Raven Press, NY, USA 613–620 (1991).
   Google Scholar
• Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam, Epilepsia43(1), 9–18 (2002).
   PubMed Web of Science ®Google Scholar
• Krauss LG, Betts T, Abou-Khalil B. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure12(8), 617–620 (2003).
   PubMed Web of Science ®Google Scholar
• Panayiotopoulos CP. Juvenile Myoclonic Epilepsy. In: The Epilepsies. Seizures, syndromes and management. Bladon Medical Publishing (2006) (In press).
   Google Scholar
• Di Bonaventura C, Fattouch J, Mari F et al. Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. Epileptic Disorders7, 231–235 (2005).
   PubMedGoogle Scholar
• Gruenewald R. Levetiracetam in the treatment of idiopathic generalized epilepsies. Epilepsia46(Suppl. 9), 154–160 (2005).
   Google Scholar
• Verdru P. Epilepsy in children: the evidence for new antiepileptic drugs. Acta Neurol. Scand.181, 17–20 (2005).
   Google Scholar
• Tan MJ, Appleton RE. Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience. Seizure13(3), 142–145 (2004).
   PubMed Web of Science ®Google Scholar
• Cross H, Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure11, 406–410 (2002).
   PubMed Web of Science ®Google Scholar
• Suzuki S, Kawakami K, Nishimura S et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res.12, 21–27 (1992).
   PubMed Web of Science ®Google Scholar
• Andriola MR, Miller MA, Vitale SJ et al. Zonisamide as adjunctive and monotherapy in absence epilepsy. Epilepsia43(Suppl. 7), 109 (2002).
   Google Scholar
• Wilfong A. Schultz R. Zonisamide for absence seizures. Epilepsy Res.64, 31–34 (2005).
   PubMed Web of Science ®Google Scholar
• Trudeau V, Myers S, LaMoreaux L et al. Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J. Child Neurol.11(6), 470–475 (1996).
   PubMed Web of Science ®Google Scholar
• Panayiotopoulos CP, Ferrie CD, Knott C et al. Interaction of lamotrigine with sodium valproate. Lancet341, 445 (1993).
   PubMed Web of Science ®Google Scholar
• Ferrie CD, Robinson RO, Knott C et al. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol. Scand.91, 200–202 (1995).
   PubMed Web of Science ®Google Scholar
• Cunnington M, Tennis P. Lamotrigine and the risk of malformation in pregnancy. Neurology64, 955–960 (2005).
   PubMed Web of Science ®Google Scholar
• Morrow JI, Russell A, Gutherie E et al. Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry77, 193–198 (2006).
   PubMed Web of Science ®Google Scholar
• Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev.22, 75–80 (2000).
   PubMed Web of Science ®Google Scholar
• Perucca E, Gram L, Avanzini G et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia39(1), 5–17 (1998).
   PubMed Web of Science ®Google Scholar
• Wallengren C, Li S, Morris MJ et al. Aggravation of absence seizures by carbamazepine in a genetic rat model does not induce neuronal c-Fos activation. Clin. Neuropharmacol.28(2), 60–65 (2005).
   Google Scholar
• Panayiotopoulos CP, Agathonikou A, Sharoqi IA et al. Vigabatrin aggravates absences and absence status. Neurology49(5), 1467 (1997).
   PubMed Web of Science ®Google Scholar
• Knake S, Hamer HM, Schomburg U et al. Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure8(5), 314–317 (1999).
   PubMed Web of Science ®Google Scholar
• Lerman-Sagie T, Watemberg N, Kramer U et al. Absence seizures aggravated by valproic acid. Epilepsia42(7), 941–943 (2001).
   PubMed Web of Science ®Google Scholar
• Horn CS, Ater SB, Hurst DL. Carbamazepine-exacerbated epilepsy in children and adolescents. Pediatr Neurol.2, 340–345 (1986).
   PubMedGoogle Scholar
• Parker APJ, Agathonikou A, Robinson RO et al. Inappropriate use of carbamazepine and vigabatrin in typical absence seizures. Dev. Med. Child Neurol.40, 517–519 (1998).
   PubMed Web of Science ®Google Scholar
• Gelisse P, Genton P, Kuate C et al. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia45, 1282–1286 (2004).
   PubMed Web of Science ®Google Scholar